Clinical Trial: Exploratory Study of Pagoclone in Men With Premature Ejaculation.

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Four-arm, Randomized, Double-blind, Parallel, Placebo-controlled Exploratory Study of Pagoclone 0.15mg, 0.30mg, and 0.60mg in Men With Primary Premature Ejaculation.

Brief Summary: The purpose of this study is to evaluate pagoclone in the treatment of premature ejaculation.

Detailed Summary: The primary objective of this study is to evaluate the effect of 3 dose levels of pagoclone (0.15 mg, 0.30 mg, and 0.60 mg) versus placebo on intravaginal ejaculation latency time (IELT) male patients with primary premature ejaculation.
Sponsor: Endo Pharmaceuticals

Current Primary Outcome: Intravaginal ejaculation latency time (IELT)

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Endo Pharmaceuticals

Dates:
Date Received: August 30, 2006
Date Started: July 2006
Date Completion:
Last Updated: December 3, 2013
Last Verified: February 2007